Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019

Leverkusen, Germany, Oct. 23, 2019 (GLOBE NEWSWIRE) — Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, was presented with the “Poster of the Day” award at the renowned Fall Clinical Dermatology Conference in Las Vegas from October 17 to 20, 2019 for its latest Phase III clinical trial.
During the conference, the company presented four scientific posters on the application of photodynamic therapy (PDT) for the treatment of actinic keratoses (AK) and basal cell carcinomas. The poster presentation of the results of the Phase III clinical trial on the safety and efficacy of conventional PDT with BF-200 ALA (development name for Ameluz®) and the BF-RhodoLED® lamp for the treatment of mild to severe AKs on the extremities or the trunk/neck (original title: Photodynamic therapy with BF-200 ALA for the treatment of mild to severe actinic keratosis on extremities and trunk/neck: Results of a randomized Phase III trial) was selected “Poster of the Day” by the attending dermatologists.“The great interest of US-dermatologists at the conference confirms the growth of the PDT market in the US. We are proud of the recognition of our positive data from our latest phase III trial with BF-200 ALA received,” commented Prof. Dr. Hermann Lübbert, Chief Executive Officer of Biofrontera. “The annual Fall Clinical Dermatology Conference offers us the opportunity to network with leading dermatologists in the US and inform them about our products.”The annual Fall Clinical Dermatology Conference is the second largest conference for dermatologists in the US and took place from October 17 to 20, 2019 in Las Vegas.-End-About Biofrontera:Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets Xepi, a prescription medication for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.